Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Core Insights - Codexis, Inc. will present three data presentations at the TIDES Europe annual meeting, showcasing the application of its ECO Synthesis™ platform for siRNA manufacturing [1][2] Group 1: Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver® technology platform [4] - The company is developing the ECO Synthesis™ manufacturing platform to enable commercial-scale production of RNAi therapeutics through enzymatic methods [4] Group 2: Industry Context - RNA as a therapeutic modality has gained significant traction, particularly with the rise of mRNA vaccines and siRNA candidates in clinical studies [2] - There are currently over 450 RNAi therapies in clinical development, with more than 40 in Phase 2 and Phase 3 trials, indicating a growing demand that is expected to exceed current production capabilities by the end of the decade [2] Group 3: ECO Synthesis Manufacturing Platform - The ECO Synthesis™ platform aims to address scalability and cost limitations in RNAi therapeutics manufacturing, potentially allowing for commercial-scale production through enzymatic routes [3] - Codexis has demonstrated high coupling efficiency greater than 98% in enzymatic synthesis, comparable to traditional phosphoramidite chemistry, while also achieving lower impurity levels [3]